Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Anticoagulant Utilization Pattern

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2013-05-07

Last Posted Date: 2019-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 333664

Registration Number: NCT01847560

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 2x500 mg Metformin (Glumetza)
Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Drug: 5 mg Linagliptin/1000 mg Metformin FDC
Drug: 3x500 mg Metformin (Glumetza)
Drug: 5 mg Linagliptin/1000mg Metformin FDC
Drug: 5 mg Linagliptin (Tradjenta)
Drug: 2 x 500 mg Metformin (Glumetza)

First Posted Date: 2013-05-03

Last Posted Date: 2014-08-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01845077

Locations: 🇺🇸
1288.8.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: empagliflozin and metformin
Drug: empagliflozin
Drug: metformin (Glucophage®)

First Posted Date: 2013-05-01

Last Posted Date: 2015-07-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01844531

Locations: 🇩🇪
1276.6.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 691751
Drug: Placebo

First Posted Date: 2013-05-01

Last Posted Date: 2016-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 81

Registration Number: NCT01843972

Locations: 🇩🇪
1334.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI-409306 25 milligram (mg) SD
Drug: BI-409306 50 mg SD
Drug: BI-409306 100 mg SD
Drug: BI-409306 100 mg MD

First Posted Date: 2013-04-26

Last Posted Date: 2024-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT01841112

Locations: 🇰🇷
1289.4.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1015550
Drug: BI1015550

First Posted Date: 2013-04-19

Last Posted Date: 2016-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01835899

Locations: 🇩🇪
1305.2.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Ribavirin
Drug: BI 207127 high dose
Drug: BI 207127 low dose
Drug: Faldaprevir

First Posted Date: 2013-04-12

Last Posted Date: 2015-11-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT01830127

Locations: 🇺🇸
1241.30.10001 Boehringer Ingelheim Investigational Site, Deland, Florida, United States
🇩🇪
1241.30.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
1241.30.49008 Boehringer Ingelheim Investigational Site, Bonn, Germany

and more 16 locations

Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin

First Posted Date: 2013-04-08

Last Posted Date: 2014-09-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 678

Registration Number: NCT01826370

Locations: 🇵🇭
Boehringer Ingelheim Investigational Site 42, Cardona, Rizal, Philippines
🇵🇭
Boehringer Ingelheim Investigational Site 24, Las Pinas, Philippines
🇵🇭
Boehringer Ingelheim Investigational Site 25, Cebu, Philippines

and more 48 locations

Pharmacokinetics of Faldaprevir of Soft Capsule

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: faldaprevir(high dose)
Drug: Faldaprevir(low dose)

First Posted Date: 2013-04-01

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT01821937

Locations: 🇨🇳
1220.52.86001 Boehringer Ingelheim Investigational Site, Beijing, China

ADAM-Afatinib Diarrhea Assessment and Management

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: afatinib
Drug: loperamide

First Posted Date: 2013-03-20

Last Posted Date: 2016-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT01814553

Locations: 🇺🇸
1200.167.01001 Boehringer Ingelheim Investigational Site, Morristown, New Jersey, United States
🇺🇸
1200.167.01009 Boehringer Ingelheim Investigational Site, Santa Rosa, California, United States
🇺🇸
1200.167.01020 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy